• Chikako Sakaguchi, Aoi Kakehi, Naoki Minami, Akira Kikuchi, and Yasuyuki Futamura.
• Japan Tobacco Inc., Product Science Division, R&D Group, Yokohama, Kanagawa, Japan. Electronic address: chikako.sakaguchi@jt.com.
• Regul. Toxicol. Pharmacol. 2014 Aug 1; 69 (3): 338-47.

AbstractThe objective of this clinical study was to investigate changes in levels of biomarkers of exposure (BOEs) in healthy Japanese male smokers who switched to a prototype heated cigarette (HC). This was a controlled, semi-randomized, open-label, residential study conducted in Japan. A total of 70 healthy Japanese male smokers were enrolled. Following enrollment, subjects smoked their usual brand of cigarette for 2days and were subsequently randomized either to an HC group or a 10mg tar conventional cigarette (CC10) group for four consecutive weeks. Levels of BOEs for ten selected cigarette smoke constituents (nicotine, carbon monoxide (CO), benzene, 1,3-butadiene, acrolein, hydrogen cyanide, crotonaldehyde, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone [NNK], pyrene, 4-aminobiphenyl), and urine mutagenicity were measured at several time points during the study period. At the end of the study period, except for blood carboxyhemoglobin, levels of BOEs for the other nine constituents and urine mutagenicity were significantly lower in the HC group compared to the CC10 group. These results suggest that exposure to most cigarette smoke constituents, except CO, can be reduced by switching from CC10 to HC.Copyright © 2014 Elsevier Inc. All rights reserved.

28 keywords...

hide…